Piramal Pharma Ltd (PPLPHARMA)
₹143.3▲0.74%
Piramal Pharma Ltd share Performance
- ₹141.5₹146₹143.3
1.26%
Low
Day's Volatility:3.14%
High
1.88%
- ₹67.92₹149₹143.3
52.60%
Low
52 Weeks Volatility:56.58%
High
3.98%
| Returns % | |
| 1 Month Return | 9.51 % |
| 3 Month Return | 0.11 % |
| 1 Year Return | 97.16 % |
| Market Stats | |
| Previous Close | ₹142.25 |
| Open | ₹142.80 |
| Volume | 32.39L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹18,818.94Cr |
Analyst Rating
based on 5 analysts
Based on 5 analysts offering long term price targets for Piramal Pharma Ltd. An average target of ₹168.4
Source: S&P Global Market Intelligence
Company Information
Share Price: ₹143.30 per share as on 29 Apr, 2024 04:01 PM
Market Capitalisation: ₹18,818.94Cr as of today
Revenue: ₹1,958.57Cr as on December 2023 (Q4 23)
Net Profit: ₹10.11Cr as on December 2023 (Q4 23)
Listing date: 19 Oct, 2022
Chairperson Name: Nandini Piramal
| Organisation | Piramal Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Piramal Pharma Ltd
Piramal Pharma Receives Positive Inspection Report from USFDA - 18 Apr, 2024
The US FDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma's Riverview manufacturing facility, leading to a 2.09% gain in the company's stock price. The pharmaceutical company also reported a consolidated net profit of Rs 10.11 crore in Q3 FY24.
ICICI Securities Gives Buy Call on Piramal Pharma with Target Price of Rs 180 - 16 Apr, 2024
ICICI Securities has given a buy call on Piramal Pharma with a target price of Rs 180. The company reported a consolidated total income of Rs 2020.08 crore for the quarter ended December 31, 2023, up 3.04% from the last quarter and up 12.32% from the same quarter last year. Promoters held 35.02% stake in the company as of December 31, 2023, while FIIs owned 32.51%, DIIs 9.68%. Net profit after tax was Rs -3.84 crore in the latest quarter.
Piramal Pharma Launches Men's Grooming Range and Reports Profit in Q3 FY24 - 10 Apr, 2024
Piramal Pharma's consumer products division has launched the BOHEM product range for men's personal grooming, aiming to cater to the male grooming market with scientifically proven ingredients. The company also reported a consolidated net profit of Rs 10.11 crore in Q3 FY24, compared to a net loss of Rs 90.18 crore in Q3 FY23.
Piramal Pharma Recommended as Short-Term Buy - 01 Apr, 2024
Piramal Pharma is recommended as a buy call for the short term, with positive momentum and strong bullish signals. A positive stance is maintained on the stock.
Piramal Pharma's Revenue Expected to Climb by 14% - 26 Mar, 2024
Piramal Pharma's P/S ratio of 2x is moderate compared to the industry. The company's revenue has been rising slower than most other companies, but it posted a worthy increase of 8.6% in the last year of revenue growth. Revenue is anticipated to climb by 14% during the coming year according to analysts.
Fundamentals of Piramal Pharma Ltd
Insights on Piramal Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 6 months, PPLPHARMA stock has moved up by 49.0%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 6.28% to 9.01% in Mar 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, PPLPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 1.80K Cr → 2.03K Cr (in ₹), with an average increase of 5.8% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -98.58 Cr → 10.11 Cr (in ₹), with an average increase of 1057.1% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 35.02% of holdings in Mar 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 22.41% to 21.89% in Mar 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 14.47% to 12.55% in Mar 2024 quarter
Piramal Pharma Ltd Valuation
Piramal Pharma Ltd in the last 5 years
Lowest (-517.48x)
April 10, 2024
Today (-507.31x)
April 26, 2024
Industry (61.93x)
April 26, 2024
Highest (101.60x)
October 19, 2022
Mutual Fund Holdings
Shareholding Pattern
| Investors | Holdings % | Prev. 1 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 35.02% | 0.00 | |
| Foreign Institutions | 12.55% | 0.00 | |
| Mutual Funds | 9.01% | 0.00 | |
| Retail Investors | 21.89% | 0.00 | |
| Others | 21.53% | 0.00 |
Technicals of Piramal Pharma Ltd share
News & Events of Piramal Pharma Ltd
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Piramal Pharma Ltd shares.
Piramal Pharma Ltd (PPLPHARMA) share price today is ₹143.3
Piramal Pharma Ltd is listed on NSE
Piramal Pharma Ltd is listed on BSE
- Today’s highest price of Piramal Pharma Ltd is ₹146.
- Today’s lowest price of Piramal Pharma Ltd is ₹141.5.
PE Ratio of Piramal Pharma Ltd is -507.31
PE ratio = Piramal Pharma Ltd Market price per share / Piramal Pharma Ltd Earnings per share
Today’s traded volume of Piramal Pharma Ltd(PPLPHARMA) is 32.39L.
Today’s market capitalisation of Piramal Pharma Ltd(PPLPHARMA) is ₹18818.94Cr.
| Piramal Pharma Ltd(PPLPHARMA | Price |
|---|---|
52 Week High | ₹149 |
52 Week Low | ₹67.92 |
Piramal Pharma Ltd(PPLPHARMA) share price is ₹143.3. It is down -3.83% from its 52 Week High price of ₹149
Piramal Pharma Ltd(PPLPHARMA) share price is ₹143.3. It is up 110.98% from its 52 Week Low price of ₹67.92
| Piramal Pharma Ltd(PPLPHARMA | Returns |
|---|---|
1 Day Returns | 1.05% |
1 Month Returns | 9.51% |
3 Month Returns | 0.11% |
1 Year Returns | 97.16% |